美国临床肿瘤学会HER2阳性进展期乳腺癌系统治疗临床实践指南(2018)更新解读
|
摘要
<正>HER2阳性乳腺癌是一种特殊类型的乳腺癌,恶性程度高,预后差。曲妥珠单抗的问世,改变了HER2阳性乳腺癌的疾病自然进程。正因如此,规范HER2阳性进展期乳腺癌病人的治疗更为重要。美国临床肿瘤学会(ASCO)曾于2014年发表了HER2阳性进展期乳腺癌系统治疗的临床实践指南,对临床产生广泛影响~([1]),近几年我国乳腺界也根据循证医学证据及国情发表了HER2阳性乳腺癌临床诊疗专家共识[2],随着
引文
[1]Giordano SH,Temin S,Kirshner JJ,et al.Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer:American Society of Clinical Oncology clinical practice guideline[J].J Clin Oncol,2014,32(19):2078-2099.
[2]江泽飞,邵志敏,徐兵河.人表皮生长因子受体2阳性乳腺癌临床诊疗专家共识2016[J].中华医学杂志,2016,96(14):1091-1096.
[3]Giordano SH,Temin S,Chandarlapaty S,et al.Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer:ASCO Clinical Practice Guideline Update[J].J Clin Oncol,2018,36(26):2736-2740.
[4]Swain SM,Baselga J,Kim SB,et al.Pertuzumab,trastuzumab,and docetaxel in HER2-positive metastatic breast cancer[J].N Engl J Med,2015,372(8):724-734.
[5]Perez EA,Barrios C,Eiermann W,et al.Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive,Advanced Breast Cancer:Primary Results From the Phase III MARIANNE Study[J].J Clin Oncol,2017,35(2):141-148.
[6]D ieras V,Miles D,Verma S,et al.Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer(EMILIA):a descriptive analysis of final overall survival results from a randomised,open-label,phase 3 trial[J].Lancet Oncol,2017,18(6):732-742.
[7]von Minckwitz G,Schwedler K,Schmidt M,et al.Trastuzumab beyond progression:overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer[J].Eur J Cancer,2011,47(15):2273-2281.
[8]Geyer CE,Forster J,Lindquist D,et al.Lapatinib plus capecitabine for HER2-positive advanced breast cancer[J].N Engl J Med,2006,355(26):2733-2743.
[9]Andersson M,Lidbrink E,Bjerre K,et al.Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer:the HERNATAstudy[J].J Clin Oncol,2011,29(3):264-271.
[10]Robert N,Leyland-Jones B,Asmar L,et al.Randomized phase IIIstudy of trastuzumab,paclitaxel,and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer[J].J Clin Oncol,2006,24(18):2786-2792.
[11]Slamon DJ,Leyland-Jones B,Shak S,et al.Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2[J].N Engl J Med,2001,344(11):783-792.
[12]Marty M,Cognetti F,Maraninchi D,et al.Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment:the M77001 study group[J].J Clin Oncol,2005,23(19):4265-4274.
[13]Blackwell KL,Burstein HJ,Storniolo AM,et al.Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer:final results from the EGF104900 Study[J].J Clin Oncol,2012,30(21):2585-2592.
[14]Kaufman B,Mackey JR,Clemens MR,et al.Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive,hormone receptor-positive metastatic breast cancer:results from the randomized phase III TAnDEM study[J].J Clin Oncol,2009,27(33):5529-5537.
[15]Johnston S,Pippen J Jr,Pivot X,et al.Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer[J].J Clin Oncol,2009,27(33):5538-5546.
[16]Extra JM,Antoine EC,Vincent-Salomon A,et al.Efficacy of trastuzumab in routine clinical practice and after progression for metastatic breast cancer patients:the observational Hermine study[J].Oncologist,2010,15(8):799-809.
[17]Viedma-Rodriguez R,Baiza-Gutman L,Salamanca-Gomez F,et al.Mechanisms associated with resistance to tamoxifen in estrogen receptor-positive breast cancer(review)[J].Oncol Rep,2014,32(1):3-15.
[18]Osborne CK,Schiff R.Mechanisms of endocrine resistance in breast cancer[J].Annu Rev Med,2011,62:233-247.
[19]Yamnik RL,Digilova A,Davis DC,et al.S6 kinase 1 regulates estrogen receptor alpha in control of breast cancer cell proliferation[J].JBiol Chem,2009,284(10):6361-6369.
[2]江泽飞,邵志敏,徐兵河.人表皮生长因子受体2阳性乳腺癌临床诊疗专家共识2016[J].中华医学杂志,2016,96(14):1091-1096.
[3]Giordano SH,Temin S,Chandarlapaty S,et al.Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer:ASCO Clinical Practice Guideline Update[J].J Clin Oncol,2018,36(26):2736-2740.
[4]Swain SM,Baselga J,Kim SB,et al.Pertuzumab,trastuzumab,and docetaxel in HER2-positive metastatic breast cancer[J].N Engl J Med,2015,372(8):724-734.
[5]Perez EA,Barrios C,Eiermann W,et al.Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive,Advanced Breast Cancer:Primary Results From the Phase III MARIANNE Study[J].J Clin Oncol,2017,35(2):141-148.
[6]D ieras V,Miles D,Verma S,et al.Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer(EMILIA):a descriptive analysis of final overall survival results from a randomised,open-label,phase 3 trial[J].Lancet Oncol,2017,18(6):732-742.
[7]von Minckwitz G,Schwedler K,Schmidt M,et al.Trastuzumab beyond progression:overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer[J].Eur J Cancer,2011,47(15):2273-2281.
[8]Geyer CE,Forster J,Lindquist D,et al.Lapatinib plus capecitabine for HER2-positive advanced breast cancer[J].N Engl J Med,2006,355(26):2733-2743.
[9]Andersson M,Lidbrink E,Bjerre K,et al.Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer:the HERNATAstudy[J].J Clin Oncol,2011,29(3):264-271.
[10]Robert N,Leyland-Jones B,Asmar L,et al.Randomized phase IIIstudy of trastuzumab,paclitaxel,and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer[J].J Clin Oncol,2006,24(18):2786-2792.
[11]Slamon DJ,Leyland-Jones B,Shak S,et al.Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2[J].N Engl J Med,2001,344(11):783-792.
[12]Marty M,Cognetti F,Maraninchi D,et al.Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment:the M77001 study group[J].J Clin Oncol,2005,23(19):4265-4274.
[13]Blackwell KL,Burstein HJ,Storniolo AM,et al.Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer:final results from the EGF104900 Study[J].J Clin Oncol,2012,30(21):2585-2592.
[14]Kaufman B,Mackey JR,Clemens MR,et al.Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive,hormone receptor-positive metastatic breast cancer:results from the randomized phase III TAnDEM study[J].J Clin Oncol,2009,27(33):5529-5537.
[15]Johnston S,Pippen J Jr,Pivot X,et al.Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer[J].J Clin Oncol,2009,27(33):5538-5546.
[16]Extra JM,Antoine EC,Vincent-Salomon A,et al.Efficacy of trastuzumab in routine clinical practice and after progression for metastatic breast cancer patients:the observational Hermine study[J].Oncologist,2010,15(8):799-809.
[17]Viedma-Rodriguez R,Baiza-Gutman L,Salamanca-Gomez F,et al.Mechanisms associated with resistance to tamoxifen in estrogen receptor-positive breast cancer(review)[J].Oncol Rep,2014,32(1):3-15.
[18]Osborne CK,Schiff R.Mechanisms of endocrine resistance in breast cancer[J].Annu Rev Med,2011,62:233-247.
[19]Yamnik RL,Digilova A,Davis DC,et al.S6 kinase 1 regulates estrogen receptor alpha in control of breast cancer cell proliferation[J].JBiol Chem,2009,284(10):6361-6369.